Regístrese
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Daptomicina en el tratamiento antimicrobiano parenteral ambulatorio
Información de la revista
Vol. 30. Núm. S1.
Daptomicina en las infecciones causadas por bacterias grampositivas
Páginas 59-63 (Febrero 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 30. Núm. S1.
Daptomicina en las infecciones causadas por bacterias grampositivas
Páginas 59-63 (Febrero 2012)
DOI: 10.1016/S0213-005X(12)70074-5
Acceso a texto completo
Daptomicina en el tratamiento antimicrobiano parenteral ambulatorio
Daptomycin in outpatient antimicrobial parenteral therapy
Visitas
2411
Carlos Cerveraa,
Autor para correspondencia
ccervera@clinic.ub.es

Autor para correspondencia.
, Carlos A. Mestresb
a Servicio de Enfermedades Infecciosas, Hospital Clínic de Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, España
b Servicio de Cirugía Cardiovascular, Hospital Clínic de Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, España
Este artículo ha recibido
2411
Visitas
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

Daptomicina es un lipopéptido cíclico con una actividad rápidamente bactericida frente a bacterias grampositivas. Su farmacocinética permite administrarla una vez al día en forma de bolo intravenoso (incluyendo bolo rápido de 2 min). Ello, unido a su excelente perfil de seguridad, la convierte en un fármaco de primera línea para su uso como tratamiento antibiótico parenteral a domicilio (TADE). La mayor evidencia de daptomicina en TADE la encontramos en infección de piel y tejidos blandos, complicada o no, e infección osteoarticular por bacterias grampositivas. Para el resto de indicaciones, el uso de daptomicina en TADE deberá ser evaluado de forma individualizada. Los datos del EUCORE español reflejan el uso de daptomicina en nuestro país, con un alto índice de éxito terapéutico, tanto en el paciente hospitalizado como en los pacientes que reciben el fármaco en régimen de hospitalización a domicilio.

Palabras clave:
Daptomicina
Tratamiento antibiótico parenteral a domicilio (TADE)
Hospitalización a domicilio
Bacterias grampositivas
Bacteriemia
Endocarditis
Infección de piel y tejidos blandos
Infección osteoarticular
Abstract

Daptomycin is a cyclic lipopeptide with a rapid bactericidal effect against Gram-positive bacteria. The pharmacokinetic properties of this drug allow once-daily intravenous infusion as the best posology (including a 2-minute bolus). Because of its ease of administration and excellent safety profile, daptomycin is a first-line agent for use as outpatient antimicrobial parenteral therapy (OPAT). The best evidence supporting this indication exists for the treatment of complicated and uncomplicated skin and soft tissue infections, as well as osteoarticular infections caused by Gram-positive bacteria. For the remaining indications, the use of daptomycin as OPAT should be analyzed in each patient. Information from the EUCORE Registry in Spain indicates that daptomycin has high rates of treatment success in both hospitalized patient and in those included in OPAT programs.

Keywords:
Daptomycin
Outpatient antimicrobial parenteral therapy
Home hospitalization
Gram-positive bacteria
Bacteremia
Endocarditis
Skin and soft tissue infection
Osteoarticular infection
El Texto completo solo está disponible en PDF
Bibliografía
[1.]
V.J. Gónzalez Ramallo.
Daptomycin in home hospitalization.
Med Clin (Barc), 135 (2010), pp. 48-54
[2.]
A.D. Tice, S.J. Rehm, J.R. Dalovisio, J.S. Bradley, L.P. Martinelli, D.R. Graham, et al.
Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines.
Clin Infect Dis, 38 (2004), pp. 1651-1672
[3.]
M.J. Rybak.
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Clin Microbiol Infect, 12 (2006), pp. 24-32
[4.]
F.B. Oleson, C.L. Berman, A.P. Li.
An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes.
Chem Biol Interact, 150 (2004), pp. 137-147
[5.]
R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein.
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis, 38 (2004), pp. 1673-1681
[6.]
V.G. Fowler Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, M.E. Rupp, et al.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
N Engl J Med, 355 (2006), pp. 653-665
[7.]
D.E. Katz, K.C. Lindfield, J.N. Steenbergen, D.P. Benziger, K.J. Blackerby, A.G. Knapp, et al.
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
Int J Clin Pract, 62 (2008), pp. 1455-1464
[8.]
D.A. Figueroa, E. Mangini, M. Amodio-Groton, B. Vardianos, A. Melchert, C. Fana, et al.
Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.
Clin Infect Dis, 49 (2009), pp. 177-180
[9.]
N. Safdar, D. Andes, W.A. Craig.
In vivo pharmacodynamic activity of daptomycin.
Antimicrob Agents Chemother, 48 (2004), pp. 63-68
[10.]
F.B. Oleson Jr., C.L. Berman, J.B. Kirkpatrick, K.S. Regan, J.J. Lai, F.P. Tally.
Once-daily dosing in dogs optimizes daptomycin safety.
Antimicrob Agents Chemother, 44 (2000), pp. 2948-2953
[11.]
Novartis Europharm, Ltd. Cubicin Summary of Product Characteristics. 2008.
[12.]
A. Chakraborty, S. Roy, J. Loeffler, R.L. Chaves.
Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection.
J Antimicrob Chemother, 64 (2009), pp. 151-158
[13.]
J.P. Horcajada, L. García, N. Benito, C. Cervera, M. Sala, A. Olivera, et al.
Specialized home care for infectious disease, Experience from 1995 to 2002.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 429-436
[14.]
A.L. Chapman, S. Dixon, D. Andrews, P.J. Lillie, R. Bazaz, J.D. Patchett.
Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.
J Antimicrob Chemother, 64 (2009), pp. 1316-1324
[15.]
R.A. Seaton, E. Sharp, V. Bezlyak, C.J. Weir.
Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections.
Int J Antimicrob Agents, 38 (2011), pp. 243-248
[16.]
Quist SR, Fierlbeck G, Seaton RA, Loeffler J, Chaves RL. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections. Int J Antimicrob Agents. En prensa. doi:10.1016/j.ijantimicag.2011.08.007.
[17.]
I. Eleftheriadou, N. Tentolouris, V. Argiana, E. Jude, A.J. Boulton.
Methicillin-resistant Staphylococcus aureus in diabetic foot infections.
[18.]
R.A. Seaton, A.A. Macconnachie.
Experience with daptomycin in an infectious diseases service over 1 year: utility in an outpatient parenteral antibiotic programme.
Int J Antimicrob Agents, 31 (2008), pp. 492-497
[19.]
W.J. Martone, K.C. Lindfield, D.E. Katz.
Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry.
Int J Clin Pract, 62 (2008), pp. 1183-1187
[20.]
B. Almirante.
Clinical experience with daptomycin use in Spain. Global findings from EU-CORE database.
Med Clin (Barc), 135 (2010), pp. 23-28
[21.]
G.N. Forrest, B.J. Donovan, K.C. Lamp, L.V. Friedrich.
Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis.
Ann Pharmacother, 42 (2008), pp. 213-217
[22.]
M.E. Falagas, K.P. Giannopoulou, F. Ntziora, P.J. Papagelopoulos.
Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence.
Int J Antimicrob Agents, 30 (2007), pp. 202-209
[23.]
I. Raad, H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel, G. Chaiban, et al.
Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillinresistant Staphylococcus bacteremic isolates embedded in biofilm.
Antimicrob Agents Chemother, 51 (2007), pp. 1656-1660
[24.]
C.E. Edmiston Jr., M.P. Goheen, G.R. Seabrook, C.P. Johnson, B.D. Lewis, K.R. Brown, et al.
Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices.
Am J Surg, 192 (2006), pp. 344-354
[25.]
C. Garrigos, O. Murillo, G. Euba, R. Verdaguer, F. Tubau, C. Cabellos, et al.
Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillinresistant Staphylococcus aureus.
Antimicrob Agents Chemother, 54 (2010), pp. 5251-5256
[26.]
Z. Kanafani, H. Boucher, V. Fowler, C. Cabell, B. Hoen, J.M. Miro, et al.
Daptomycin compared to standard therapy for the treatment of native valve endocarditis.
Enferm Infecc Microbiol Clin, 28 (2010), pp. 498-503
[27.]
C. Cervera, A. Del Río, L. García, M. Sala, M. Almela, A. Moreno, et al.
Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study.
Enferm Infecc Microbiol Clin, 29 (2011), pp. 587-592
[28.]
D. Stamboulian, P. Bonvehi, C. Arevalo, R. Bologna, I. Cassetti, V. Scilingo, et al.
Antibiotic management of outpatients with endocarditis due to penicillinsusceptible streptococci.
Rev Infect Dis, 13 (1991), pp. S160-S163
[29.]
J.M. Colford Jr., R.L. Corelli, J.W. Ganz, B.J. Guglielmo, R.A. Jacobs.
Home antibiotic therapy for streptococcal endocarditis: a call for a controlled trial.
Am J Med, 94 (1993), pp. 111-112
[30.]
P. Francioli, J. Etienne, R. Hoigne, J.P. Thys, A. Gerber.
Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy outpatient treatment feasibility.
JAMA, 267 (1992), pp. 264-267
[31.]
D. Huminer, J. Bishara, S. Pitlik.
Home intravenous antibiotic therapy for patients with infective endocarditis.
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 330-334
[32.]
M.M. Andrews, C.F. Von Reyn.
Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis.
Clin Infect Dis, 33 (2001), pp. 203-209
[33.]
J. Larioza, L. Heung, A. Girard, R.B. Brown.
Management of infective endocarditis in outpatients: clinical experience with outpatient parenteral antibiotic therapy.
South Med J, 102 (2009), pp. 575-579
[34.]
M.R. Amodeo, T. Clulow, J. Lainchbury, D.R. Murdoch, K. Gallagher, A. Dyer, et al.
Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes.
J Infect, 59 (2009), pp. 387-393
[35.]
C.A. Monteiro, C.G. Cobbs.
Outpatient management of infective endocarditis.
Curr Infect Dis Rep, 3 (2001), pp. 319-327
[36.]
C. Cervera, X. Castaneda, J.M. Pericàs, A. Del Río, C.G. De la María, C. Mestres, et al.
Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
Int J Antimicrob Agents, 38 (2011), pp. 365-370
[37.]
J. Ho, S. Archuleta, Z. Sulaiman, D. Fisher.
Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service.
J Antimicrob Chemother, 65 (2010), pp. 2641-2644
[38.]
D.P. Levine, K.C. Lamp.
Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Am J Med, 12010 (2007), pp. S28-S33
[39.]
C.A. Arias, D. Panesso, D.M. McGrath, X. Qin, M.F. Mojica, C. Miller, et al.
Genetic basis for in vivo daptomycin resistance in enterococci.
N Engl J Med, 365 (2011), pp. 892-900
[40.]
C. García-de-la-María, F. Marco, Y. Armero, D. Soy, A. Moreno, A. Del Río, et al.
Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
Antimicrob Agents Chemother, 54 (2010), pp. 2781-2786
[41.]
P. Dohmen, A. Guleri, N. Petrosillo, R. Utili, V. González-Sanz, R. Seaton, et al.
Daptomycin for the treatment of infective endocarditis: results from European Cubicin Outcomes Registry and Experience (EUCORE) [abstract O512]. 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna.
Austria, (2010),
[42.]
E.O. Gómez, A. Jafary, L.L. Dever.
Daptomycin and rifampin for the treatment of methicillin-resistant Staphylococcus aureus septic pulmonary emboli in the absence of endocarditis.
Microb Drug Resist, 16 (2010), pp. 241-244
[43.]
B.H. Heintz, J. Halilovic, C.L. Christensen.
Vancomycin-resistant enterococcal urinary tract infections.
Pharmacotherapy, 30 (2010), pp. 1136-1149
[44.]
T. Kelesidis, R. Humphries, K. Ward, M.A. Lewinski, O.O. Yang.
Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia.
Diagn Microbiol Infect Dis, 71 (2011), pp. 286-290
[45.]
J. Le, P.B. Bookstaver, C.N. Rudisill, M.G. Hashem, R. Iqbal, C.L. James, et al.
Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.
Ann Pharmacother, 44 (2010), pp. 2001-2006
Copyright © 2012. Elsevier España S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.